Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic
effect on remote and non-irradiated tumor deposits, which is called abscopal effect. The view …

Abstract Background Immune checkpoint inhibitors (ICIs) have improved cancer outcomes.
However, immune-related adverse effects are common. The aim was to investigate the …

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell
death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have …

In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …

The standard of care for patients with stage III non-small-cell lung cancer (NSCLC) is
concurrent chemoradiotherapy (CCRT) followed by 1 year of adjuvant durvalumab. Despite …

Introduction Consolidation durvalumab after chemoradiation (CRT) is the current standard of
care for locally advanced NSCLC. We hypothesized that adding immunotherapy …

Importance Consolidative programmed death ligand-1 (PD-L) inhibition after
chemoradiotherapy improves overall survival and progression-free survival (PFS) for stage …

Immune checkpointty inhibitors (ICIs), particularly those targeting programmed death 1 (PD-
1) and anti-programmed death ligand 1 (PD-L1), enhance the antitumor effect by restoring …

Historically, non-small-cell lung cancer (NSCLC) has been regarded as a nonimmunogenic
tumor; however, recent studies have shown that NSCLCs are among the most responsive …